



an Open Access Journal by MDPI

Antimicrobials Use: Clinical Safety to Environmental Risk—Learning from One Health Approach

Guest Editors:

Dr. Anabela Almeida

Escola Universitária Vasco da Gama (EUVG), Campus Universitário, Av. José R. Sousa Fernandes, Coimbra, Portugal

Dr. Leonor M. Meisel

Research Institute for Medicines – iMED.Ulisboa, Lisboa, Portugal

Dr. Ana Fortuna

Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions:

30 September 2026

Message from the Guest Editors

Dear Colleagues,

Antimicrobials, including antibiotic, antiviral and antifungal drugs, are increasingly assuming an important role in global public health. They are especially relevant considering emergent infectious diseases.

Significant challenges in the human and veterinary clinical setting are rising due to AMR. Increasing risks in this topic demand new approaches: for instance, triggering further PK/PD procedures. Therefore, monitoring programs are essential to supervise consumption and AMR data trends to further understand the issue and anticipate/implement measures.

Data are scarce concerning antimicrobial resistance’s monitoring in surface water and groundwater, environmental fate and ecotoxicological effects, mainly regarding antiviral and antifungal drugs. To perform prioritisation analysis, it is also essential to know the relationship between their consumption in human or animal settings and environment occurrence.

Thus, in the view of the One Health engagement, optimising the use of antimicrobial medicines in human and animal health and the environmental charge is a crucial procedure for surveillance and minimisation of the potential risks.



mdpi.com/si/127868



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi